Resumo

BUSTIOS SANCHEZ, Carla; SUMIRE UMERES, Julia; ASATO HIGA, Carmen  e  MONGE ZAPATA, Victor. Terbinafine-induced liver toxicity in the context of a SARS-CoV-2 pandemic: a case report. Rev. gastroenterol. Perú [online]. 2021, vol.41, n.2, pp.107-111. ISSN 1022-5129.  http://dx.doi.org/10.47892/rgp.2021.412.1280.

Terbinafine is a drug that can induce acute liver damage. We present the case of a 40-year-old male patient who developed liver dysfunction after 35 days of terbinafine treatment for onychomycosis. The anatomopathological study showed: acute hepatitis in resolution, in addition to ductopenia and cholestasis. These findings, without a history of viral or autoimmune hepatitis, are consistent with the diagnosis of drug-induced liver damage (DILI). In this report we present the first case in our country of a patient who is affected by an acute liver disease: terbinafine-induced liver injury, to which SARS-CoV-2 infection was later associated in the context of a pandemic.

Palavras-chave : Acute liver injury, drug-induced; Terbinafine; SARS-CoV-2.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )